Everybody has been waiting for the Food and Drug Administration to finish its safety review of the abortion drug mifepristone. This study, prompted by evidence that the drugs are more dangerous to women than previously supposed, is meant to inform changes the administration might make to the drug’s long-term FDA regulations. Reporting suggests that the study is now seriously underway and on track, which is welcomed news. However, any subsequent regulations are likely to be challenged in court by the abortion lobby and subject to lengthy litigation.
In the meantime, there’s another decision of utmost importance the administration has to make about abortion drugs — one that relies not on the FDA, but on Acting Attorney General Todd Blanche, who has been nominated as attorney general and awaits confirmation in the Senate. That’s the decision about whether, before the study is completed and the long-term regulations are set, we should still follow the Biden rules that everyone involved (other than the abortion industry, that is) admits are both dangerous and illegal.
